Explore
Validate
Learn
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [61]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-11367 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-ErbB2 (HER-2) (Tyr1248) Monoclonal Antibody (PN2A)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- MA5-11367 targets Phospho-HER-2 pTyr1248 in IF, IHC, and WB applications and shows reactivity with Human and Rat samples.
- Antibody clone number
- PN2A
- Concentration
- 0.2 mg/mL
Submitted references Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC.
Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.
A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.
Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method.
Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway.
TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.
High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Designed TPR modules as novel anticancer agents.
Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.
Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma.
Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements.
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis.
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Differential localization of ErbB receptor ensembles influences their signaling in hippocampal neurons.
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells.
Synergistic interactions between tamoxifen and trastuzumab (Herceptin).
Synergistic interactions between tamoxifen and trastuzumab (Herceptin).
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
Profiling receptor tyrosine kinase activation by using Ab microarrays.
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Almotlak AA, Farooqui M, Siegfried JM
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Jan;15(1):62-79
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Jan;15(1):62-79
Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR, McMahon S, Forrest ME, Bartels CF, Saiakhova A, Bartel CA, Scacheri PC, Thompson CL, Jackson MW, Harris LN, Khalil AM
Oncotarget 2016 Aug 16;7(33):53230-53244
Oncotarget 2016 Aug 16;7(33):53230-53244
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, Gómez-Miragaya J, González-Suárez E, Puig T
PloS one 2015;10(6):e0131241
PloS one 2015;10(6):e0131241
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL
BMC cancer 2014 May 8;14:326
BMC cancer 2014 May 8;14:326
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sørensen BS, Lykkesfeldt AE
Cancer letters 2014 Mar 1;344(1):90-100
Cancer letters 2014 Mar 1;344(1):90-100
V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.
von Schwarzenberg K, Lajtos T, Simon L, Müller R, Vereb G, Vollmar AM
Molecular oncology 2014 Feb;8(1):9-19
Molecular oncology 2014 Feb;8(1):9-19
A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.
Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL
Laboratory investigation; a journal of technical methods and pathology 2014 Apr;94(4):467-74
Laboratory investigation; a journal of technical methods and pathology 2014 Apr;94(4):467-74
Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method.
Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF
PloS one 2013;8(11):e79901
PloS one 2013;8(11):e79901
Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway.
Kuo HP, Hsu SC, Ou CC, Li JW, Tseng HH, Chuang TC, Liu JY, Chen SJ, Su MH, Cheng YC, Chou WY, Kao MC
Evidence-based complementary and alternative medicine : eCAM 2013;2013:219472
Evidence-based complementary and alternative medicine : eCAM 2013;2013:219472
TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
Deng X, Fogh L, Lademann U, Jensen V, Stenvang J, Yang H, Brünner N, Schrohl AS
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013 Apr;34(2):1161-70
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013 Apr;34(2):1161-70
EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Cortés MA, Cariaga-Martinez AE, Lobo MV, Martín Orozco RM, Motiño O, Rodríguez-Ubreva FJ, Angulo J, López-Ruiz P, Colás B
Carcinogenesis 2012 Jun;33(6):1169-77
Carcinogenesis 2012 Jun;33(6):1169-77
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC
European journal of cancer (Oxford, England : 1990) 2012 Dec;48(18):3488-98
European journal of cancer (Oxford, England : 1990) 2012 Dec;48(18):3488-98
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA
Journal of cellular physiology 2011 Jan;226(1):52-7
Journal of cellular physiology 2011 Jan;226(1):52-7
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Huang X, Wang S, Lee CK, Yang X, Liu B
Cancer letters 2011 Aug 1;307(1):72-79
Cancer letters 2011 Aug 1;307(1):72-79
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S, Huang X, Lee CK, Liu B
Oncogene 2010 Jul 22;29(29):4225-36
Oncogene 2010 Jul 22;29(29):4225-36
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B
Cancer research 2010 Feb 1;70(3):1204-14
Cancer research 2010 Feb 1;70(3):1204-14
High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.
Treekitkarnmongkol W, Suthiphongchai T
World journal of gastroenterology 2010 Aug 28;16(32):4047-54
World journal of gastroenterology 2010 Aug 28;16(32):4047-54
High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.
Treekitkarnmongkol W, Suthiphongchai T
World journal of gastroenterology 2010 Aug 28;16(32):4047-54
World journal of gastroenterology 2010 Aug 28;16(32):4047-54
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G
Breast cancer research : BCR 2009;11(4):R50
Breast cancer research : BCR 2009;11(4):R50
Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD
Molecular cancer research : MCR 2009 Nov;7(11):1882-92
Molecular cancer research : MCR 2009 Nov;7(11):1882-92
HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B
Cancer research 2009 Nov 1;69(21):8403-11
Cancer research 2009 Nov 1;69(21):8403-11
Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.
Singer CF, Hudelist G, Fuchs EM, Köstler W, Fink-Retter A, Gschwantler-Kaulich D, Gnant M, Lamm W, Rudas M, Czerwenka K, Kubista E
Endocrine-related cancer 2009 Mar;16(1):73-83
Endocrine-related cancer 2009 Mar;16(1):73-83
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L
Cell cycle (Georgetown, Tex.) 2009 Jul 1;8(13):2050-6
Cell cycle (Georgetown, Tex.) 2009 Jul 1;8(13):2050-6
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L
Cell cycle (Georgetown, Tex.) 2009 Jul 1;8(13):2050-6
Cell cycle (Georgetown, Tex.) 2009 Jul 1;8(13):2050-6
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M, Giovannini M
Oncogene 2009 Feb 12;28(6):854-65
Oncogene 2009 Feb 12;28(6):854-65
Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY
Breast cancer research and treatment 2008 Sep;111(2):241-50
Breast cancer research and treatment 2008 Sep;111(2):241-50
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F
Cancer research 2008 Oct 1;68(19):8127-36
Cancer research 2008 Oct 1;68(19):8127-36
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX
Cancer research 2008 Nov 15;68(22):9280-90
Cancer research 2008 Nov 15;68(22):9280-90
Designed TPR modules as novel anticancer agents.
Cortajarena AL, Yi F, Regan L
ACS chemical biology 2008 Mar 20;3(3):161-6
ACS chemical biology 2008 Mar 20;3(3):161-6
Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
Chakraborty AK, Liang K, DiGiovanna MP
Cancer research 2008 Mar 1;68(5):1538-45
Cancer research 2008 Mar 1;68(5):1538-45
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.
Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar VB
Cancer research 2008 Jan 15;68(2):483-91
Cancer research 2008 Jan 15;68(2):483-91
Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma.
Xu S, Kitayama J, Yamashita H, Souma D, Nagawa H
Journal of surgical oncology 2008 Jan 1;97(1):44-50
Journal of surgical oncology 2008 Jan 1;97(1):44-50
Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA
Cell proliferation 2008 Feb;41(1):59-85
Cell proliferation 2008 Feb;41(1):59-85
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, Teng M, Liu J
Proteins 2008 Feb 15;70(3):938-49
Proteins 2008 Feb 15;70(3):938-49
Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements.
Szabó A, Horváth G, Szöllosi J, Nagy P
Biophysical journal 2008 Aug;95(4):2086-96
Biophysical journal 2008 Aug;95(4):2086-96
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 15;13(20):6175-81
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 15;13(20):6175-81
Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
Vazquez-Martin A, Colomer R, Menendez JA
European journal of cancer (Oxford, England : 1990) 2007 May;43(7):1117-24
European journal of cancer (Oxford, England : 1990) 2007 May;43(7):1117-24
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD
International journal of cancer 2007 May 1;120(9):1874-82
International journal of cancer 2007 May 1;120(9):1874-82
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F
European journal of cancer (Oxford, England : 1990) 2007 Mar;43(4):725-35
European journal of cancer (Oxford, England : 1990) 2007 Mar;43(4):725-35
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.
Xu W, Yuan X, Beebe K, Xiang Z, Neckers L
Molecular and cellular biology 2007 Jan;27(1):220-8
Molecular and cellular biology 2007 Jan;27(1):220-8
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R, López-Ruiz P, Colás B
Neoplasia (New York, N.Y.) 2007 Aug;9(8):614-24
Neoplasia (New York, N.Y.) 2007 Aug;9(8):614-24
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R, López-Ruiz P, Colás B
Neoplasia (New York, N.Y.) 2007 Aug;9(8):614-24
Neoplasia (New York, N.Y.) 2007 Aug;9(8):614-24
Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis.
Stonecypher MS, Chaudhury AR, Byer SJ, Carroll SL
Journal of neuropathology and experimental neurology 2006 Feb;65(2):162-75
Journal of neuropathology and experimental neurology 2006 Feb;65(2):162-75
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Hansen MR, Roehm PC, Chatterjee P, Green SH
Glia 2006 Apr 15;53(6):593-600
Glia 2006 Apr 15;53(6):593-600
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G
Immunology letters 2006 Apr 15;104(1-2):146-55
Immunology letters 2006 Apr 15;104(1-2):146-55
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD
Breast cancer research : BCR 2005;7(5):R708-18
Breast cancer research : BCR 2005;7(5):R708-18
Differential localization of ErbB receptor ensembles influences their signaling in hippocampal neurons.
Chen J, Tseng HC, Dichter MA, Zhang H, Greene MI
DNA and cell biology 2005 Sep;24(9):553-62
DNA and cell biology 2005 Sep;24(9):553-62
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
Stewart LV, Lyles B, Lin MF, Weigel NL
The Journal of steroid biochemistry and molecular biology 2005 Oct;97(1-2):37-46
The Journal of steroid biochemistry and molecular biology 2005 Oct;97(1-2):37-46
Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
Friedländer E, Arndt-Jovin DJ, Nagy P, Jovin TM, Szöllosi J, Vereb G
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2005 Oct;67(2):161-71
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2005 Oct;67(2):161-71
A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R
Oncogene 2005 Jan 27;24(5):761-79
Oncogene 2005 Jan 27;24(5):761-79
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J, Carothers Carraway CA, Muller WJ, Carraway KL
Journal of cellular physiology 2005 Apr;203(1):44-53
Journal of cellular physiology 2005 Apr;203(1):44-53
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Apr 10;23(11):2460-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Apr 10;23(11):2460-8
Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells.
Menendez JA, Ropero S, Lupu R, Colomer R
Annals of oncology : official journal of the European Society for Medical Oncology 2004 Nov;15(11):1719-21
Annals of oncology : official journal of the European Society for Medical Oncology 2004 Nov;15(11):1719-21
Synergistic interactions between tamoxifen and trastuzumab (Herceptin).
Argiris A, Wang CX, Whalen SG, DiGiovanna MP
Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Feb 15;10(4):1409-20
Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Feb 15;10(4):1409-20
Synergistic interactions between tamoxifen and trastuzumab (Herceptin).
Argiris A, Wang CX, Whalen SG, DiGiovanna MP
Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Feb 15;10(4):1409-20
Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Feb 15;10(4):1409-20
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.
Mano MS, Awada A, Minisini A, Durbecq V, Di Leo A, Piccart M
Breast (Edinburgh, Scotland) 2004 Aug;13(4):347-9
Breast (Edinburgh, Scotland) 2004 Aug;13(4):347-9
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
Hudelist G, Köstler WJ, Attems J, Czerwenka K, Müller R, Manavi M, Steger GG, Kubista E, Zielinski CC, Singer CF
British journal of cancer 2003 Sep 15;89(6):983-91
British journal of cancer 2003 Sep 15;89(6):983-91
Profiling receptor tyrosine kinase activation by using Ab microarrays.
Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK
Proceedings of the National Academy of Sciences of the United States of America 2003 Aug 5;100(16):9330-5
Proceedings of the National Academy of Sciences of the United States of America 2003 Aug 5;100(16):9330-5
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Murillo H, Schmidt LJ, Tindall DJ
Cancer research 2001 Oct 15;61(20):7408-12
Cancer research 2001 Oct 15;61(20):7408-12
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, Cui J, Sun L, Wei J, Cherrington JM, Mendel DB
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):4230-8
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):4230-8
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of Phospho-HER-2/ErbB2 pTyr1248 was done on 70% confluent log phase T47D cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with of Phospho-HER-2/ErbB2 pTyr1248 (PN2A) Mouse Monoclonal Antibody (Product # MA5-11367) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing cytoplasmic localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Kaplan-Meier curve of p27 Kip1 and HER2 pY1248 in Herceptin(tm)-treated breast cancer patients. (a) Dichotomised p27 Kip1 immunohistochemistry ( P = 0.012) and (b) phosphorylated HER2 receptor immunohistochemistry ( P = 0.016). HER = human epidermal growth factor receptor.
